Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Odc1MHCI-P30
- Development stage
- Preclinical
- Lead developer
- Duke University
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
**Odc1MHCI-P30** is an experimental conjoined peptide neoantigen vaccine developed at Duke University for glioblastoma. It links an MHC class I-restricted neoepitope derived from ornithine decarboxylase 1 with the universal CD4 T-cell helper epitope P30 in a single peptide construct. In syngeneic murine glioblastoma models, the conjoined construct induced interferon-gamma-secreting immune responses and antitumor activity; combining vaccination with an anti-CD27 agonist further enhanced immune activity and long-term survival. It is a preclinical therapeutic cancer-vaccine construct and has no assigned INN or marketed brand name.
- Other names
- Odc1MHCI-P30Odc-1MHCI-P30Odc 1MHCI-P30
02
Targets
MHC I (MHC class I})TCR-P30-MHCII (T-cell receptor recognizing Tetanus Toxin P30–MHC II complex)T-cell receptor recognizing Ornithine decarboxylase 1–Major Histocompatibility Complex Class I complexMHC II (Major histocompatibility complex class II receptor)ODC1 (Ornithine decarboxylase)
Beyond the preview
Go deeper on Odc1MHCI-P30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Odc1MHCI-P30.